Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children

Medicina

Volumn 67, Issue 4, 2007, Pages 351-359

  Avila Aguero, Maria Luisa ^a   Soriano Fallas, Alejandra ^a   De Los Angeles Umaña Sauma, Maria ^a   Ulloa Gutierrez, Rolando ^a   Arnoux, Sabine ^b  

^a HOSPITAL NACIONAL DE NIÑOS   (Costa Rica)

^b SANOFI PASTEUR   (France)

Author keywords

Children; High risk; Immunogenicity; Inactivated influenza vaccine; Safety

Indexed keywords

HEMAGGLUTININ; IMOVAX GRIPE; INACTIVATED VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ANTIBODY TITER; ARTHRALGIA; ARTICLE; ASTHENIA; BRONCHOPNEUMONIA; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSENTERY; ECCHYMOSIS; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INJECTION SITE BLEEDING; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MAJOR CLINICAL STUDY; MALE; MYALGIA; OPEN STUDY; PRESCHOOL CHILD; RESPIRATORY DISTRESS; RESPIRATORY TRACT DISEASE; SEROCONVERSION; SHIVERING; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; VIRUS STRAIN;

ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; COSTA RICA; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HEMAGGLUTININS, VIRAL; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; RESPIRATORY TRACT DISEASES; RISK FACTORS; VACCINES, INACTIVATED;

EID: 34548499558     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Committee on Infectious Diseases. American Academy of Pediatrics; Policy Statement: Reduction of the Influenza Burden in Children. Pediatrics 2002; 110: 1246-52.
2. Rennels MB, Meissner HC and the Committee on Infectious Diseases. American Academy of Pediatrics. Technical Report: Reduction of the Influenza Burden in Children. Pediatrics 2002; 110:e80. In: http://www.pediatrics.org/cgi/content/full/110/6/e80; accessed 8 January 2007.
3. Simonsen L. The Global Impact of Influenza on Morbidity and Mortality. Vaccine 1999; 17: S3-S10.
4. Neuzil KM, Yuwel Z, Griffin MR, et al. Burden of Interpandemic Influenza in Children Younger than 5 years: A 25-Year Prospective Study. J Infect Dis 2002; 185: 147-52.
5. World Health Organization. Influenza vaccines. Weekly Epidemiological Record No 35, 2000; 75: 281-8. In: http://www.who.int/docstore/wer/pdf/ 2000/wer7535.pdf; accessed 8 January 2007.
6. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2004; 53(RR06): 1-40.
7. Committee on Infectious Diseases. Recommendations for influenza immunization of children. Pediatrics 2004; 113; 1441-7.
8. Ruben FL. Inactivated influenza vaccines in children. Clinical Infectious Diseases 2004; 38: 678-88.
9. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirements for influenza vaccine. (CPMP/BWP/214/ 96). In: http://www.emea.eu.int/pdfs/human/bwp/021496en.pdf; accessed 8 January 2007.
10. European Agency for the Evaluation of Medicinal Products/Committee for Proprietary Medicinal Products (CPMP). Harmonization of requirements for influenza vaccines. London: Human Medicines Evaluation Unit 1997: 15-9.
11. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): prevention and control of influenza. MMWR Morb Mortal Wkly Rep 2002; 1(RR-3): 1-31.
12. Gonzalez M, Pirez MC, Ward E, Dibarboure H, Garcia A, Picolet H. Safety and immunogenicity of a paediatric presentation of an influenza vaccine. Arch Dis Child 2000; 83: 488-91.
13. Lina B, Fletcher MA, Valette M, Saliou P, Aymard M. A TritonX-100-split virion influenza vaccine is safe and fulfills the Committee for Proprietary Medicinal Products (CPMP) recommendations for the European Community for Immunogenicity in Children, Adults and the Elderly. Biologicals. 2000; 28: 95-103.
14. Morales A, Salazar JA, Salazar Y, et al. A randomized controlled trial comparing split and subunit influenza vaccines in adults in Colombia. Medicina (Buenos Aires) 2003; 63: 197-204.
15. Daubeney P, Taylor CJ, McGaw J, et al. Immunogenicity and tolerability of a trivalent influenza subunit vaccine (Influvac) in high-risk children aged 6 months to 4 years. Br J Clin Pract 1997; 51: 87-90.
16. Groothuis JR, Lehr MV, Levin MJ. Safety and immunogenicity of a purified haemagglutin antigen in very young high-risk children. Vaccine 1994; 12: 139-41.
17. Groothuis JR, Levin MJ, Rabelais GP, Meikeljohn G, Lauer BA. Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine. Pediatrics 1991; 87: 823-8.